While both atosiban and hexoprenaline are effective for halting uterine contractions during fetal distress, atosiban seems to cause fewer maternal adverse events, faster resumption of contractions (8 vs. 14 minutes, respectively), and can be given faster as an IV bolus (1 vs. 5 minutes, respectively), according to a prospective, randomized pilot trial.
Austrian researchers studied 1,431 women with singleton, cephalic presentation, term pregnancies. Tocolysis was achieved in 92% of the atosiban group and in 100% of the hexoprenaline group. Only one woman in the atosiban group showed no reaction to the drug, which could be due to the fact that the drug was administered during the second stage of labor; all other women receiving the agent received it during the first stage.
Afschar P, Scholl W, Bader A, et al. A prospective randomized trial of atosiban versus hexoprenaline for acute tocolysis and intrauterine resuscitation. BJOG. 2004;111:316-318.
Fasting glucose at GDM diagnosis may predict postpartum glucose abnormalities
February 6th 2025A recent study suggests that elevated fasting glucose levels at the time of gestational diabetes diagnosis could be an early indicator of postpartum glucose intolerance, emphasizing the need for close monitoring after delivery.
Read More
Ulipristal plus misoprostol shows promise for medication abortion
February 5th 2025A recent study found that ulipristal acetate followed by misoprostol is a safe, effective, and acceptable option for medication abortion, offering a potential alternative in areas with limited access to mifepristone.
Read More
Identification and management of patients at increased risk for breast cancer
February 5th 2025With breast cancer being the most diagnosed invasive cancer in the United States, OB-GYN practitioners play a crucial role in identifying high-risk patients and guiding them through screening, prevention, and risk-reduction strategies.
Read More